. home.aspx



Charity backs R&D into Parkinson’s drugs targeting mitochondria

July 01, 2019 / Richard Staines

The charity Parkinson’s UK has struck a £1 million partnership with NRG Therapeutics to develop drugs targeted at mitochondria that could protect cells producing dopamine, which have been damaged by the condition. The research will build on recent discoveries showing a direct link between mitochondrial dysfunction and the loss of dopamine cells. Parkinson’s UK will invest up to £1 million in NRG Therapeutics to develop and translate this research into a potential therapeutic drug. NRG Therapeutics is a new UK-based biotech developing novel drugs acting through preservation of mitochondrial function, targeting degenerative diseases such as Parkinson’s, Alzheimer’s disease and motor neuron disease. Dr Arthur Roach, director of research at Parkinson’s UK, has joined the board of NRG Therapeutics as a non-executive director. He said: “We all know there is a tremendous need to find better treatments for Parkinson’s that can slow down the...